MO34-3 The efficacy of combined EGFR-TKI plus VEGF inhibitor/cytotoxic therapy for PD-L1-positive EGFR-mutant NSCLC: NJLCG2202.
Saved in:
| Title: | MO34-3 The efficacy of combined EGFR-TKI plus VEGF inhibitor/cytotoxic therapy for PD-L1-positive EGFR-mutant NSCLC: NJLCG2202. |
|---|---|
| Authors: | Kawashima, Y.1 (AUTHOR), Inomata, M.2 (AUTHOR), Saito, R.3 (AUTHOR), Morinaga, D.4 (AUTHOR), Nogawa, H.5 (AUTHOR), Satou, M.6 (AUTHOR), Suzuki, Y.7 (AUTHOR), Yanagisawa, S.8 (AUTHOR), Kikuchi, T.9 (AUTHOR), Jingu, D.10 (AUTHOR), Yoshimura, N.11 (AUTHOR), Harada, T.12 (AUTHOR), Miyauchi, E.3 (AUTHOR) |
| Source: | Annals of Oncology. Oct2024:Supplement 3, Vol. 35, pS1344-S1345. 2p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2024.07.573 |
